Elequin Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Elequin Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24K	Sell	127 -141	-53%	-$24.6K	﹤0.01%	240
2025 Q4	$45.6K	Buy	+268	New	+$41.1K	﹤0.01%	147
2025 Q1	–	Sell	-210	Closed	-$25.9K	–	483
2024 Q4	$25.9K	Buy	210 +183	+678%	+$21.6K	﹤0.01%	224
2024 Q3	$3.01K	Buy	+27	New	+$2.96K	﹤0.01%	313
2024 Q2	–	Sell	-107	Closed	-$12.9K	–	271
2024 Q1	$12.9K	Buy	+107	New	+$13.1K	﹤0.01%	74
2023 Q3	–	Sell	-108	Closed	-$13.4K	–	507
2023 Q2	$13.4K	Buy	+108	New	+$14.5K	0.01%	270
2022 Q4	–	Sell	-120	Closed	-$16K	–	673
2022 Q3	$16K	Sell	120 -184	-61%	-$28K	0.01%	177
2022 Q2	$47K	Buy	304 +35	+13%	+$5.39K	0.01%	138
2022 Q1	$42K	Buy	+269	New	+$39K	0.01%	73

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Elequin Capital's JAZZ Position: Q1 2026 in Review

Elequin Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 53% in Q1 2026, selling an estimated $24.6K and leaving 127 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #240.

Elequin Capital first reported a position in JAZZ in Q1 2022 and has held it in 9 quarters since. The position peaked at $47K in Q2 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Elequin Capital held 127 shares of Jazz Pharmaceuticals worth $24K as of Q1 2026.
Elequin Capital sold 141 Jazz Pharmaceuticals shares in Q1 2026, an estimated $24.6K.
Jazz Pharmaceuticals made up ﹤0.01% of Elequin Capital's portfolio in Q1 2026, its #240 holding.
Elequin Capital first reported a position in Jazz Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
Elequin Capital's Jazz Pharmaceuticals position peaked at $47K in Q2 2022.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Elequin Capital's 13F filing for Q1 2026, filed 11 May 2026.